Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
accepted:
05
12
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
24
1
2024
Statut:
aheadofprint
Résumé
Cabotegravir long-acting (CAB-LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, which demonstrated superior reduction in HIV-1 acquisition compared with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in men who have sex with men (MSM), transgender women (TGW), and cisgender women. A decision-analytic model was developed to assess the lifetime cost-effectiveness of initiating CAB-LA versus generic oral FTC/TDF for HIV PrEP in the USA from a healthcare sector perspective. PrEP-eligible adults entered the Markov model receiving CAB-LA or FTC/TDF and could continue initial PrEP, transition to a second PrEP option, or discontinue PrEP over time. Efficacy was taken from the HPTN 083 and HPTN 084 clinical trials. Individuals who acquired HIV-1 infection incurred lifetime HIV-related costs, could transmit HIV onwards, and could develop PrEP-related resistance mutations. Input parameter values were obtained from public and published sources. Model outcomes were discounted at 3%. The model estimated that the CAB-LA pathway prevented 4.5 more primary and secondary HIV-1 infections per 100 PrEP users than the oral PrEP pathway, which yielded 0.2 fewer quality-adjusted life-years (QALYs) lost per person. Additional per-person lifetime costs were $9476 (2022 US dollars), resulting in an incremental cost-effectiveness ratio of $46,843 per QALY gained. Results remained consistent in sensitivity and scenario analyses, including in underserved populations with low oral PrEP usage. Our analysis suggests that initiating CAB-LA for PrEP is cost-effective versus generic daily oral FTC/TDF for individuals at risk of acquiring HIV-1 infection.
Identifiants
pubmed: 38267806
doi: 10.1007/s40273-023-01342-y
pii: 10.1007/s40273-023-01342-y
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
CDC. Diagnoses of HIV infection in the United States and dependent areas, 2019. May 2021. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html . Accessed 1 Nov 2022.
CDC. Ending the HIV epidemic. April 1, 2021. https://www.cdc.gov/endhiv/index.html . Accessed 1 Nov 2022.
DESCOVY PI. DESCOVY
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
doi: 10.1056/NEJMoa1402269
pubmed: 25651245
pmcid: 4341965
Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6): e1003670.
doi: 10.1371/journal.pmed.1003670
pubmed: 34143779
pmcid: 8253429
CDC. US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Centers for Disease Control and Prevention; December 2021. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf . Accessed 1 Nov 2022.
Oglesby A, Germain G, Laliberte F, Bush S, Swygard H, MacKnight S, et al. Real-world persistency of patients receiving tenofovir-based pre-exposure prophylaxis for the prevention of HIV infection in the US. In: Presented at the Infectious Disease Week (IDWeek) Conference, Virtual. 29 Sep-3 Oct, 2021.
CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. May 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-vol-26-no-2.pdf . Accessed 1 Nov 2022.
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608.
doi: 10.1056/NEJMoa2101016
pubmed: 34379922
pmcid: 8448593
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779–89.
doi: 10.1016/S0140-6736(22)00538-4
pubmed: 35378077
pmcid: 9077443
APRETUDE PI. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use. ViiV Healthcare; December 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf . Accessed 1 Nov 2022.
Chen A, Dowdy DW. Clinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-making. PLoS ONE. 2014;9(10): e108742.
doi: 10.1371/journal.pone.0108742
pubmed: 25285793
pmcid: 4186823
Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806–15.
doi: 10.1086/597095
pubmed: 19193111
Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative pricing of branded tenofovir alafenamide-emtricitabine relative to generic tenofovir disoproxil fumarate-emtricitabine for HIV preexposure prophylaxis: a cost-effectiveness analysis. Ann Intern Med. 2020;172(9):583–90.
doi: 10.7326/M19-3478
pubmed: 32150602
pmcid: 7217721
Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022;175(4):479–89.
doi: 10.7326/M21-1548
pubmed: 35099992
pmcid: 9087297
Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238–43.
doi: 10.1016/j.annepidem.2017.02.003
pubmed: 28325538
pmcid: 5524204
Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infection treatment guidelines, 2021. MMWRR Recomm Rep. 2021;70(4):39.
CDC. Interpretation of hepatitis B serologic test results. https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf . Accessed 1 Nov 2022.
Schillie S, Wester C, Osburne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(2):1–17.
Landovitz RJ, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L. HPTN 083 final results: pre-exposure prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men. In: Presented at the AIDS 2020 Conference, Virtual. 6–10 July, 2020.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.
doi: 10.1001/jama.2016.12195
pubmed: 27623463
Serota DP, Rosenberg ES, Sullivan PS, Thorne AL, Rolle CM, Del Rio C, et al. Pre-exposure prophylaxis uptake and discontinuation among young black men who have sex with men in Atlanta, Georgia: a prospective cohort study. Clin Infect Dis. 2020;71(3):574–82.
doi: 10.1093/cid/ciz894
pubmed: 31499518
Kelley CF, Kahle E, Siegler A, Sanchez T, Del Rio C, Sullivan PS, Rosenberg ES. Applying a PrEP continuum of care for men who have sex with men in Atlanta. Georgia Clin Infect Dis. 2015;61(10):1590–7.
doi: 10.1093/cid/civ664
pubmed: 26270691
Grinsztejn B, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L. HPTN 083: efficacy of pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations. In: Presented at the AIDS 2020 Conference, Virtual. 6–10 July, 2020.
Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009. Glob Health Sci Pract. 2013;1(2):203–12.
doi: 10.9745/GHSP-D-13-00010
pubmed: 25276533
pmcid: 4168565
Mera R, Scheer S, Carter C, Das M, Asubonteng J, McCallister S, Baeten J. Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the metropolitan statistical area level in the United States. J Int AIDS Soc. 2019;22(12): e25433.
doi: 10.1002/jia2.25433
pubmed: 31860171
pmcid: 7086379
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.
doi: 10.1016/S1473-3099(14)70847-3
pubmed: 25065857
pmcid: 6107918
Marzinke M, Grinsztejn B, Fogel J, Piwowar EM, Hanscom B, Coelho L. Laboratory analysis of HIV infections in HPTN 083: injectable CAB for PrEP [oral abstract]. In: Presented at the Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts. 6–10 March, 2021.
Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, Weidle PJ, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013Oct;64(2):183–9.
doi: 10.1097/QAI.0b013e3182973966
pubmed: 23615000
TRUVADA PI. TRUVADA
Merative Micromedex Solutions. Red Book. 2022. https://www.micromedexsolutions.com/home/dispatch/ssl/true . Accessed 15 Apr 2021.
CMS.gov. Physician fee schedule. 1 July 2022. https://www.cms.gov/medicare/physician-fee-schedule/search/overview . Accessed 23 Aug 2022.
Cohen JP, Beaubrun A, Ding Y, Wade RL, Hines DM. Estimation of the incremental cumulative cost of HIV compared with a non-HIV population. Pharmacoecon Open. 2020;4(4):687–96.
doi: 10.1007/s41669-020-00209-8
pubmed: 32219732
pmcid: 7688860
US Bureau of Labor Statistics. Consumer price index for Medical Care. 2022. https://data.bls.gov/cgi-bin/surveymost?cu . Accessed Jan 2022.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services; 21 September 2022. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf . Accessed 1 Nov 2022.
Beck EJ, Mandalia S, Lo G, Sharott P, Youle M, Anderson J, et al. Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996–2006. PLoS ONE. 2011;6(5): e20200.
doi: 10.1371/journal.pone.0020200
pubmed: 21633514
pmcid: 3102104
Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349–61.
doi: 10.1007/s40273-015-0327-2
pubmed: 26660529
Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–7.
doi: 10.1056/NEJMp1405158
pubmed: 25162885
Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349–56.
doi: 10.1097/MLR.0b013e31815c31a7
pubmed: 18362813
Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis. In: Presented at the AIDS Conference, Montreal, Canada and virtual. 29 July–2 August, 2022.
Mitchell KM, Boily MC, Hanscom B, Moore M, Todd J, Paz-Bailey G, et al. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. Lancet Reg Health Am. 2023Feb;18: 100416.
pubmed: 36844011
pmcid: 9950652
Moore M, Donnell DJ, Boily MC, Mitchell KM, Delany-Moretlwe S, Hosseinipour M, et al. Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP. Presented at the The International AIDS Society (IAS), Virtual. 18–21 July, 2021. Available at: https://theprogramme.ias2021.org/Abstract/Abstract/1303 . Accessed 25 Aug 2023.
Torres-Rueda S, Terris-Prestholt F, Gafos M, Indravudh PP, Giddings R, Bozzani F, et al. Health economics research on non-surgical biomedical HIV prevention: identifying gaps and proposing a way forward. Pharmacoeconomics. 2023Jul;41(7):787–802.
doi: 10.1007/s40273-022-01231-w
pubmed: 36905570
pmcid: 10007656
Sarri G, Soriano Gabarro M, Cheng R, Jhutti-Johal J. Gender and health equity in health care decision-making: how women’s issues continue to be neglected. In: Presented at: ISPOR Europe. Copenhagen, Denmark; 12–15 November 2023.
CDC. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2021; and preexposure prophylaxis (PrEP) data reported through December 2020. July 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-2-no-3/cdc-hiv-surveillance-tables-vol-2-no-3.pdf . Accessed 1 Nov 2022.
Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2018. NCHS data brief no 355. Hyattsville, MD: National Center for Health Statistics; January 2020. https://www.cdc.gov/nchs/data/databriefs/db355-h.pdf . Accessed 1 Nov 2022.
Mayer K, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–54.
doi: 10.1016/S0140-6736(20)31065-5
pubmed: 32711800
pmcid: 9665936
CDC. US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline [Draft]. Centers for Disease Control and Prevention; 2021.